Furthermore, emerging data support expanded indications in non-diabetic populations, patients with CKM syndrome, microvascular dysfunction, and metabolic liver disease
In laboratory models, this pathway is observed to: Modulate neural pathways associated with satiety and appetite signalling
AOD-9604 has no safety data past six months, so long-term risk profiles and the durability of weight loss are unknown
The first month on tirzepatide involves numerous adjustments happening simultaneously, and thirst is just one of them
Wegovy is a UK-licensed pharmaceutical used to support significant and sustainable weight loss
This guide provides evidence-based dietary recommendations to help patients optimize their nutrition, manage side effects, and support their metabolic health goals during tirzepatide therapy